Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
CONTEXT: There is currently no medical therapy for Cushing's disease that targets the pituitary adenoma. Availability of such a medical therapy would be a valuable therapeutic option for the management of this disorder. OBJECTIVE: Our objective was to evaluate the short-term efficacy of the nov...
Main Authors: | Boscaro, M, Ludlam, W, Atkinson, B, Glusman, J, Petersenn, S, Reincke, M, Snyder, P, Tabarin, A, Biller, B, Findling, J, Melmed, S, Darby, C, Hu, K, Wang, Y, Freda, P, Grossman, AB, Frohman, L, Bertherat, J |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
Predictive factors and the management of hyperglycemia in patients with acromegaly and Cushing’s disease receiving pasireotide treatment: post hoc analyses from the SOM230B2219 study
by: Ulla Feldt-Rasmussen, et al.
Published: (2024-03-01) -
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
by: Richard A. Feelders, et al.
Published: (2023-10-01) -
Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.
by: Biller, B, et al.
Published: (2008) -
Incretin Response to Mixed Meal Challenge in Active Cushing’s Disease and after Pasireotide Therapy
by: Mattia Barbot, et al.
Published: (2022-05-01) -
Pasireotide: A new option for treatment of acromegaly
by: Filiz Eksi Haydardedeoglu, et al.
Published: (2020-06-01)